1-12 of 12
Thomas M Habermann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transformation in Marginal Zone Lymphoma: Results from a Prospective Cohort and a Meta-Analysis of the Literature

Clinical Trials & Observations
Côme Bommier, Brian L Link, Brianna J Gysbers, Matthew J Maurer, Melissa C Larson, Arushi Khurana, Yucai Wang, Carrie A Thompson, Dai Chihara, Juan Pablo Alderuccio, Jean L Koff, Narendranath Epperla, Annarita Conconi, Izidore S Lossos, Grzegorz S. Nowakowski, Andrew L Feldman, Thomas M Habermann, Rebecca L King, James R Cerhan
Journal: Blood Advances
Blood Adv bloodadvances.2024013188.
https://doi.org/10.1182/bloodadvances.2024013188
Published: 2024
Includes: Supplemental data
Journal Articles

Defining primary refractory large B-cell lymphoma

Allison M. Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers, Brad S. Kahl, Peter Martin, Jonathon B. Cohen, Carla Casulo, Izidore S. Lossos, Umar Farooq, Sabarish Ayyappan, Tanner Reicks, Thomas M. Habermann, Thomas E. Witzig, Christopher R. Flowers, James R. Cerhan, Loretta J. Nastoupil, Grzegorz S. Nowakowski
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3402–3415.
https://doi.org/10.1182/bloodadvances.2024012760
Published: 2024
Includes: Supplemental data
Journal Articles

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

Clinical Trials & Observations
Kurt S. Bantilan, Alexandra N. Smith, Matthew J. Maurer, Julie Teruya-Feldstein, Matthew J. Matasar, Alison J. Moskowitz, David J. Straus, Ariela Noy, M. Lia Palomba, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, James R. Cerhan, Thomas M. Habermann, Gilles A. Salles, Grzegorz S. Nowakowski, Craig H. Moskowitz, Andrew D. Zelenetz
Journal: Blood Advances
Blood Adv (2024) 8 (9): 2172–2181.
https://doi.org/10.1182/bloodadvances.2023011408
Published: 2024
Includes: Supplemental data
Journal Articles

Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy

Jessica F. Burlile, Kelsey M. Frechette, William G. Breen, Steven R. Hwang, Alexandra S. Higgins, Adrienne N. Nedved, William S. Harmsen, Sydney D. Pulsipher, Thomas E. Witzig, Ivana N. Micallef, Bradford S. Hoppe, Thomas M. Habermann, Gita Thanarajasingam, Patrick B. Johnston, David J. Inwards, N. Nora Bennani, Jennifer L. Peterson, Bradley J. Stish, William G. Rule, Stephen M. Ansell, Scott C. Lester
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1250–1257.
https://doi.org/10.1182/bloodadvances.2023011533
Published: 2024
Includes: Supplemental data
Journal Articles

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma

Clinical Trials & Observations
Raphael E. Steiner, Steven R. Hwang, Arushi Khurana, Thomas M. Habermann, Narendranath Epperla, Kaitlin Annunzio, Pamela Blair Allen, Katelin Baird, Darina Paulino, Juan Pablo Alderuccio, Izidore S. Lossos, Kevin David, Andrew M. Evens, Karan Pandya, Steven M. Bair, Manali Kamdar, Sheeba Ba Aqeel, Pallawi Torka, Ryan Lynch, Stephen Smith, Lei Feng, Mansoor Noorani, Sairah Ahmed, Ranjit Nair, Francisco Vega, Susan Wu, Penny Fang, Chelsea C. Pinnix, Jillian R. Gunther, Bouthaina S. Dabaja, Hun J. Lee
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7485–7493.
https://doi.org/10.1182/bloodadvances.2023010700
Published: 2023
Includes: Supplemental data
Journal Articles

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Clinical Trials & Observations
Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey V. Danilov, Natalie S. Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven I. Park, David A. Bond, Mehdi Hamadani, Timothy S. Fenske, Peter Martin, Mary-Kate Malecek, Brad S. Kahl, Christopher R. Flowers, Brian K. Link, Lawrence D. Kaplan, David J. Inwards, Andrew L. Feldman, Eric D. Hsi, Kami Maddocks, Kristie A. Blum, Nancy L. Bartlett, James R. Cerhan, John P. Leonard, Thomas M. Habermann, Matthew J. Maurer, Jonathon B. Cohen
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2287–2296.
https://doi.org/10.1182/bloodadvances.2022009225
Published: 2023
Includes: Supplemental data
Journal Articles

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy

Clinical Trials & Observations
Evandro D. Bezerra, Madiha Iqbal, Javier Munoz, Arushi Khurana, Yucai Wang, Matthew J. Maurer, Radhika Bansal, Matthew A. Hathcock, Nora Bennani, Hemant S. Murthy, Allison C. Rosenthal, Jonas Paludo, Jose C. Villasboas, Patrick B. Johnston, Thomas M. Habermann, Stephen M. Ansell, Januario E. Castro, Thomas E. Witzig, Mohamed A. Kharfan-Dabaja, Grzegorz S. Nowakowski, Yi Lin
Journal: Blood Advances
Blood Adv (2023) 7 (8): 1572–1576.
https://doi.org/10.1182/bloodadvances.2022007868
Published: 2023
Includes: Supplemental data
Journal Articles

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

Clinical Trials & Observations
Sanjal H. Desai, Raphael Mwangi, Wern Lynn Ng, Rebecca L. King, Matthew J. Maurer, James R. Cerhan, Andrew L. Feldman, Umar Farooq, Eric Mou, Thomas M. Habermann, Carrie A. Thompson, Yucai Wang, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood Advances
Blood Adv (2022) 6 (24): 6180–6186.
https://doi.org/10.1182/bloodadvances.2022007569
Published: 2022
Includes: Supplemental data
Journal Articles

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study

Aung M. Tun, Arushi Khurana, Raphael Mwangi, Brian K. Link, Yucai Wang, Andrew L. Feldman, Carrie A. Thompson, Anne J. Novak, Jose C. Villasboas, Gita Thanarajasingam, Umar Farooq, Sergei Syrbu, Grzegorz S. Nowakowski, Thomas E. Witzig, Stephen M. Ansell, Lisa M. Rimsza, James R. Cerhan, Thomas M. Habermann, Matthew J. Maurer
Journal: Blood Advances
Blood Adv (2022) 6 (17): 5210–5221.
https://doi.org/10.1182/bloodadvances.2022007990
Published: 2022
Includes: Supplemental data
Journal Articles

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome

Clinical Trials & Observations
Karan L. Chohan, Jason R. Young, Scott Lester, Muhamad Alhaj Moustafa, Allison Rosenthal, Han W. Tun, Bradford S. Hoppe, Patrick B. Johnston, Ivana N. Micallef, Thomas M. Habermann, Stephen M. Ansell
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4241–4250.
https://doi.org/10.1182/bloodadvances.2022007363
Published: 2022
Includes: Supplemental data
Journal Articles

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes

Clinical Trials & Observations
Alessia Castellino, Yucai Wang, Melissa C. Larson, Matthew J. Maurer, Brian K. Link, Umar Farooq, Andrew L. Feldman, Sergei I. Syrbu, Thomas M. Habermann, Jonas Paludo, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Cristine Allmer, Susan L. Slager, Jonathon B. Cohen, Peter Martin, James R. Cerhan, Grzegorz S. Nowakowski
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1350–1360.
https://doi.org/10.1182/bloodadvances.2021005715
Published: 2022
Includes: Supplemental data
Journal Articles

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

Clinical Trials & Observations
Arushi Khurana, Mattia Novo, Grzegorz S. Nowakowski, Kay M. Ristow, Robert J. Spinner, Christopher H. Hunt, Rebecca L. King, Daniel H. Lachance, Thomas M. Habermann, Ivana N. Micallef, Patrick B. Johnston
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1379–1387.
https://doi.org/10.1182/bloodadvances.2020003666
Published: 2021
Includes: Supplemental data